sitagliptin/metformin krka filmuhúðuð tafla 50 mg/1000 mg
krka, d.d., novo mesto - sitagliptinum inn; metforminum hýdróklóríð - filmuhúðuð tafla - 50 mg/1000 mg
sitagliptin/metformin krka filmuhúðuð tafla 50 mg/850 mg
krka, d.d., novo mesto - sitagliptinum inn; metforminum hýdróklóríð - filmuhúðuð tafla - 50 mg/850 mg
sitagliptin/metformin medical valley filmuhúðuð tafla 50mg/850 mg
medical valley invest ab - sitagliptinum hýdróklóríð; metforminum hýdróklóríð - filmuhúðuð tafla - 50mg/850 mg
edistride
astrazeneca ab - dapagliflozin própandiolól einhýdrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - lyf notuð við sykursýki - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. auk þess önnur lyf fyrir meðferð tegund sykursýki 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 og 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.
forxiga
astrazeneca ab - dapagliflozin própandiolól einhýdrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - lyf notuð við sykursýki - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. auk þess önnur lyf fyrir meðferð tegund sykursýki 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 og 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.
qtern
astra zeneca ab - saxagliptin, dapagliflozin propanediol einhýdrat - diabetes mellitus, type 2; diabetes mellitus; nutritional and metabolic diseases; metabolic diseases; glucose metabolism disorders - lyf notuð við sykursýki - qtern, fastur skammt sambland af saxagliptin og dapagliflozin, er ætlað í fullorðnir 18 ára og eldri með tegund sykursýki 2:til að bæta blóðsykursstjórnun þegar sjúklingar og/eða sulphonylurea (su) og einn af monocomponents af qtern veita ekki fullnægjandi blóðsykursstjórnun,þegar þegar í meðferð með frjáls sambland af dapagliflozin og saxagliptin. (sjá kafla 4. 2, 4. 4, 4. 5 og 5. 1 fyrir boði gögn um sturtu rannsakað.
sitagliptin/metformin sandoz filmuhúðuð tafla 50/1000 mg
sandoz a/s* - metforminum hýdróklóríð; sitagliptinum hýdróklóríð - filmuhúðuð tafla - 50/1000 mg
sitagliptin/metformin medical valley filmuhúðuð tafla 50mg/1000 mg
medical valley invest ab - metforminum hýdróklóríð; sitagliptinum hýdróklóríð - filmuhúðuð tafla - 50mg/1000 mg
sitagliptin/metformin zentiva (sitagliptin metformin zentiva) filmuhúðuð tafla 50 mg/1000 mg
zentiva k.s.* - metforminum hýdróklóríð; sitagliptinum hýdróklóríð - filmuhúðuð tafla - 50 mg/1000 mg
sitagliptin/metformin zentiva (sitagliptin metformin zentiva) filmuhúðuð tafla 50 mg/850 mg
zentiva k.s.* - metforminum hýdróklóríð; sitagliptinum hýdróklóríð - filmuhúðuð tafla - 50 mg/850 mg